Solna

• Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer … Recruiting
  2024-516982-35-00 5 2025-09-11 Ovarian Cancer
• Optimizing endocrine treatment > 5 years after surgery for breast cancer patients: a registry-based randomized clinical trial Recruiting
  2023-506135-14-00 11 2025-09-10 Breast cancer
• Open-Label followed by a Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Infigratinib in Children with Hypo … Recruiting
  2024-516822-67-00 10 2025-08-14 Hypochondroplasia
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph … Recruiting
  2023-509630-19-00 5 2025-07-31 Esophageal Squamous Cell Carcinoma (ESCC)
• Restarting Early versus Later Anticoagulation for Chronic Subdural Hematoma with Atrial Fibrillation (RELACS) Recruiting
  2025-521179-29-00 10 2025-07-06 Chronic subdural hematoma
• A study to understand if sotagliflozin improves symptoms and is safe in people with hypertrophic cardiomyopathy Recruiting
  2024-513869-39-00 5 2025-06-27 Obstructive Cardiomyopathy, Hypertrophic
• Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting
  2024-517423-40-00 5 2025-06-23 Metastatic Castration-Resistant Prostate Cancer
• SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melano … Recruiting
  2024-519593-39-00 5 2025-06-10 Malignant melanoma stage III
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona … Recruiting
  2024-517457-27-00 5 2025-06-04 Chronic Obstructive Pulmonary Disease (COPD)
• A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's … Recruiting
  2023-509391-42-00 11 2025-06-02 Chron's Disease
• Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 … Recruiting
  2023-508196-36-00 4 2025-05-27 Follicular lymphoma
• A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting
  2024-517147-31-00 9 2025-05-23 Tumours, Gynecological
• Long-term study evaluating joint health in people with haemophilia A receiving real-world prophylactic treatment with efanesoctocog alfa Recruiting
  2024-517812-31-00 6 2025-05-21 Haemophilia A
• A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting
  2023-506327-29-00 5 2025-05-14 Non-Small Cell Lung Cancer
• A trial to learn how well surovatamig (AZD0486) works and how safe it is in adults with certain blood cancers Recruiting
  2023-505789-27-00 4 2025-04-14 Relapsed or Refractory Non-Hodgkin Lymphoma
• RandomizEd compariSOn of apixaban versus warfarin in patients with Left VEntricular thrombus after Acute Myocardial Infarction (RESOLVE-AMI) … Recruiting
  2024-514416-28-00 6 2025-04-09 Left ventricular thrombosis.
• A Phase 3 Efficacy and Safety Study of Pitolisant in Patients with Prader-Willi Syndrome Recruiting
  2023-508307-21-00 5 2025-03-19 Prader-Willi syndrome
• Thrombolysis in Factor Xa-inhibitors Trial (SIFT) Recruiting
  2023-509907-34-01 5 2025-03-10 acute ischemic stroke
• Phase 1 study to evaluate [18F]ACI-15916 as a potential PET radioligand for imaging α-synuclein deposits in the brain of patients with suspe … Recruiting
  2024-515664-31-00 1 2025-03-04 Parkinson's Disease
• Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting
  2022-500747-21-00 4 2025-02-27 Geographic Atrophy
• A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum Recruiting
  2024-514306-31-00 5 2025-02-13 Pyoderma gangrenosum
• A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and it … Recruiting
  2023-508126-95-00 1 2025-02-10 The target population of the trial consists of patients with locally a
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col

Showing 121–144 of 390 trials